Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Upcoming SlideShare
Loading in …5
×

Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market

175 views

Published on

IntroductionWhile some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.Features and benefitsAnalysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010'19 in the seven major pharmaceutical markets Segmentation of incident cases by age group, menopausal status, stage of disease and subtype In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage HighlightsHerceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis's iniparib), even if it retains its breast cancer indication.The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.Your key questions answeredValidate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market

  • Be the first to comment

  • Be the first to like this

Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) -Triple-negative breast cancer offers a significant opportunity to newmarket entrants while Herceptin dominates the HER-2-positivemarketPublished on November 2010 Report SummaryIntroductionWhile some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet needremains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positivebreast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.Features and benefitsAnalysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leaderinterviewsEpidemiological forecasts of breast cancer incidence and prevalence for the period 201019 in the seven major pharmaceuticalmarketsSegmentation of incident cases by age group, menopausal status, stage of disease and subtypeIn-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy anddisease stageHighlightsHerceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse,retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflectingthe lack of clinical data showing that switching to Tykerb is beneficial.Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of thisindication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g.Sanofi Aventiss iniparib), even if it retains its breast cancer indication.The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior inmetastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if theyare to achieve extensive uptake.Your key questions answeredValidate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake fornew productsUnderstand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populationsEnhance commercial positioning by increasing understanding of current dynamics within the breast cancer marketStakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 1/5in dominates the HER-2-positive market (From Slideshare)
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTABLE OF CONTENTSOverview 1Catalyst 1Summary 1About Datamonitor Healthcare 3About the Oncology pharmaceutical analysis team 3Executive Summary 5Scope of the analysis 5Datamonitor insight into the hormone receptor-negative breast cancer market 5Contributing experts 7Related reports 7Upcoming related reports 71. Introduction and Scope 10Coverage of the Stakeholder Insight Survey 102. Epidemiology 11Introduction and background 11Key points 11Disease definition and diagnosis criteria 12Global variation and historical trends 12Risk factors 15Epidemiologic forecasting of breast cancer 17Description of methods 21Epidemiologic Forecast Results 23Discussion 30Conclusions 323. Disease overview 33Introduction 33Patient segmentation 354. Treatment options 39Introduction 395. Treatment Trends: Stage IIII 45Triple-negative breast cancer 45HER-2-positive breast cancer 596. Treatment Trends: Stage IV and Relapse 80Triple-negative breast cancer 80HER-2-positive breast cancer 1137. Future Treatment 144Late-phase pipeline products overview 144Future treatment scenarios 196BIBLIOGRAPHY 201Chapter 2. Epidemiology 201Chapter 3. Disease Overview 207Chapter 4. Treatment Options 209Chapter 5. Treatment Trends: Stage IIII Breast Cancer 211Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 2/5in dominates the HER-2-positive market (From Slideshare)
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer 212Chapter 7. Future Treatment 214APPENDIX A 219Abbreviations 219Physician research methodology 219Physician sample breakdown 220Contributing experts 221APPENDIX B 222The survey questionnaire 222Datamonitor consulting 276Disclaimer 277Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 3/5in dominates the HER-2-positive market (From Slideshare)
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a signi ficant opportunity to new market entrants while Herceptin dominates the HER-2-positive market Product Formats Please select the product formats and the quantity you require. 1 User License--USD 15 200.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 4/5in dominates the HER-2-positive market (From Slideshare)
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 5/5in dominates the HER-2-positive market (From Slideshare)

×